{| class="wikitable" style="text-align:center; width:100%;"
! colspan="4" style="color:white; font-size:125%; background-color:#31a354" align="center" |'''Section editors'''
|-
| style="background-color:#F0F0F0; width:15%" |[[File:Shruti.jpg|frameless|upright=0.3|center]]
| style="width:35%" |<big>[[User:Shrutichaturvedi|Shruti Chaturvedi, MBBS, MSCI]]<br>Johns Hopkins University<br>Baltimore, MD</big><br>[https://www.linkedin.com/in/shruti-chaturvedi-bb83b126/ LinkedIn]
| style="background-color:#F0F0F0; width:15%" |[[File:Tillman_Benjamin-2.jpg|frameless|upright=0.3|center]]
| style="width:35%" |<big>[[User:Benjamintillman|Benjamin Tillman, MD]]<br>Vanderbilt University<br>Nashville, TN</big>
|-
|}
''Note that there is a considerable literature on using these agents in the prevention of thromboembolism associated with atrial fibrillation and mechanical heart valves. As these conditions are out of the purview of HemOnc.org, this page primarily focuses on the prevention and treatment of venous thromboembolism (VTE).''
<br>'''Other pages on HemOnc.org regarding management of deep vein thrombosis (DVT) and pulmonary embolism (PE) include:'''
*[[Bleeding with anticoagulation]]
*[[Deep veins and superficial veins in the arms and legs]]
*[[Hypercoagulable state (thrombophilia)]] evaluation
*[[Compression stockings and sleeves]] for management and prophylaxis against postphlebitic (postthrombotic) syndrome<ref>[http://circ.ahajournals.org/content/121/8/e217.full Circulation patient page about postthrombotic syndrome (PTS)]</ref>

{| class="wikitable" style="float:right; margin-right: 5px;"
|-
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
|}
{{TOC limit|limit=3}}
=Guidelines=
==ACCP==
*'''2012:''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278049/ Antithrombotic Therapy for VTE Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines]

==[https://www.asco.org/ ASCO]==
*'''2015:''' Lyman et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881372/ ASCO Clinical Practice Guideline on VTE prophylaxis and treatment 2014 update] 
*'''2013:''' Lyman et al. [http://ascopubs.org/doi/abs/10.1200/JCO.2013.49.1118 Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update] [https://www.ncbi.nlm.nih.gov/pubmed/23669224 PubMed]

===Older===
*'''2013:''' Lyman et al. [http://jco.ascopubs.org/content/31/17/2189.long ASCO Clinical Practice Guideline on VTE prophylaxis and treatment 2013 update] [https://www.ncbi.nlm.nih.gov/pubmed/23669224 PubMed]

==[https://www.hematology.org/ ASH]==
*'''2018:''' Sch√ºnemann et al. [http://www.bloodadvances.org/content/2/22/3198 American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients]
*'''2018:''' Lim et al. [http://www.bloodadvances.org/content/2/22/3226 American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism]
*'''2018:''' Witt et al. [http://www.bloodadvances.org/content/2/22/3257 American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy]
*'''2018:''' Monagle et al. [http://www.bloodadvances.org/content/2/22/3292 American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism]
*'''2018:''' Bates et al. [http://www.bloodadvances.org/content/2/22/3317 American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy]
*'''2018:''' Cuker et al. [http://www.bloodadvances.org/content/2/22/3360 American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia]

==[http://www.esmo.org/ ESMO]==
*'''2010:''' [http://www.thrombosisresearch.com/article/S0049-3848(10)70028-1/pdf Venous thromboembolism (VTE) in cancer patients. ESMO clinical recommendations for prevention and management] [https://www.ncbi.nlm.nih.gov/pubmed/20433989 PubMed]

==IMWG==
===Current===
*'''2010:''' [http://imwg.myeloma.org/imwg-guidelines-for-the-prevention-of-thalidomide-and-lenalidomide-associated-thrombosis-in-myeloma/ IMWG guidelines for the prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma]

===Older===
*'''2007:''' [https://www.nature.com/leu/journal/v22/n2/full/2405062a.html Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma] [https://www.ncbi.nlm.nih.gov/pubmed/18094721 PubMed]

==ITAC-CME==
*'''2016:''' [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30369-2/fulltext International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer] [https://www.ncbi.nlm.nih.gov/pubmed/27733271 PubMed]

=VTE primary prophylaxis=
==Apixaban monotherapy {{#subobject:9958a4|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 10-14 days {{#subobject:734aaa|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;"
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
!Comparator
![[Levels_of_Evidence#Efficacy|Efficacy]]
![[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.nejm.org/doi/10.1056/NEJMoa0810773 Lassen et al. 2009 (ADVANCE-1)]]
| style="background-color:#1a9851" |Phase III (E)
|[[#Enoxaparin_monotherapy|Enoxaparin]]
| style="background-color:#ffffbf" |Seems not superior
| style="background-color:#91cf60" |Seems to have lower bleeding rate
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)62125-5/fulltext Lassen et al. 2010 (ADVANCE-2)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Enoxaparin_monotherapy|Enoxaparin]]
| style="background-color:#1a9850" |Superior composite endpoint
| style="background-color:#d9ef8b" |Might have lower bleeding rate
|-
|}
====Preceding treatment====
*Total knee replacement
====Anticoagulation====
*[[Apixaban (Eliquis)]] 2.5 mg PO twice per day, beginning 12 to 24 h after wound closure 

'''10- to 14-day course'''

===Variant #2, 35 days {{#subobject:15ab8c|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;"
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
!Comparator
![[Levels_of_Evidence#Efficacy|Efficacy]]
![[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.nejm.org/doi/10.1056/NEJMoa1006885 Lassen et al. 2010 (ADVANCE-3)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Enoxaparin_monotherapy|Enoxaparin]]
| style="background-color:#1a9850" |Superior composite endpoint
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Preceding treatment====
*Total hip replacement
====Anticoagulation====
*[[Apixaban (Eliquis)]] 2.5 mg PO twice per day, beginning 12 to 24 h after wound closure 

'''35-day course'''

===References===
# '''ADVANCE-1:''' Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009 Aug 6;361(6):594-604. Erratum in: N Engl J Med. 2009 Oct 29;361(18):1814. [https://www.nejm.org/doi/10.1056/NEJMoa0810773 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19657123 PubMed]
# '''ADVANCE-2:''' Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P; ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010 Mar 6;375(9717):807-15. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)62125-5/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20206776 PubMed]
# '''ADVANCE-3:''' Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM; ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010 Dec 23;363(26):2487-98. [https://www.nejm.org/doi/10.1056/NEJMoa1006885 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21175312 PubMed]

==Aspirin monotherapy {{#subobject:2b1389|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:e721b6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(00)02110-3/fulltext Rodgers et al. 2000 (PEP)]
| style="background-color:#1a9851" |Phase III (E)
|Placebo
| style="background-color:#1a9850" |Superior VTE rate
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa035572 Landolfi et al. 2004 (ECLAP)]
| style="background-color:#1a9851" |Phase III (E)
|Placebo
| style="background-color:#91cf60" |Seems to have superior rate of nonfatal myocardial infarction, nonfatal stroke, pulmonary embolism, major venous thrombosis, or death from cardiovascular causes
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.31.6844 Palumbo et al. 2011]
| style="background-color:#1a9851" |Phase III (E)
|1. [[#Enoxaparin_monotherapy|Enoxaparin]]<br> 2. Low-dose warfarin
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://www.bloodjournal.org/content/119/4/933.long Larocca et al. 2011]
| style="background-color:#1a9851" |Phase III (E)
|[[#Enoxaparin_monotherapy|Enoxaparin]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://annals.org/aim/fullarticle/1692573/aspirin-versus-low-molecular-weight-heparin-extended-venous-thromboembolism-prophylaxis Anderson et al. 2013 (EPCAT)]
| style="background-color:#1a9851" |Phase III (E)
|Dalteparin
| style="background-color:#eeee01" |Non-inferior VTE rate at 90 days
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1712746 Anderson et al. 2018 (EPCAT II)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Rivaroxaban_monotherapy|Rivaroxaban]]
| style="background-color:#eeee01" |Non-inferior VTE rate at 90 days
|-
|}
====Anticoagulation====
*[[Aspirin]] 81 to 160 mg PO once per day

'''Various durations, see individual trials'''
===References===
# '''PEP:''' Rodgers A, MacMahon S, Collins R, Prentice C; Pulmonary Embolism Prevention (PEP) trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet. 2000 Apr 15;355(9212):1295-302. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(00)02110-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/10776741 PubMed]
# '''ECLAP:''' Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T; European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004 Jan 8;350(2):114-24. [https://www.nejm.org/doi/full/10.1056/NEJMoa035572 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/14711910 PubMed]
# Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F, Rossi D, Gentilini F, Crippa C, Galli M, Nozzoli C, Ria R, Marasca R, Montefusco V, Baldini L, Elice F, Callea V, Pulini S, Carella AM, Zambello R, Benevolo G, Magarotto V, Tacchetti P, Pescosta N, Cellini C, Polloni C, Evangelista A, Caravita T, Morabito F, Offidani M, Tosi P, Boccadoro M. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol. 2011 Mar 10;29(8):986-93. Epub 2011 Jan 31. [http://ascopubs.org/doi/full/10.1200/JCO.2010.31.6844 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21282540 PubMed]
# Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A, Cavalli M, Stanevsky A, Corradini P, Pezzatti S, Patriarca F, Cavo M, Peccatori J, Catalano L, Carella AM, Cafro AM, Siniscalchi A, Crippa C, Petrucci MT, Yehuda DB, Beggiato E, Di Toritto TC, Boccadoro M, Nagler A, Palumbo A. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood. 2012 Jan 26;119(4):933-9. Epub 2011 Aug 11. [http://www.bloodjournal.org/content/119/4/933.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21835953 PubMed]
# '''EPCAT:''' Anderson DR, Dunbar MJ, Bohm ER, Belzile E, Kahn SR, Zukor D, Fisher W, Gofton W, Gross P, Pelet S, Crowther M, MacDonald S, Kim P, Pleasance S, Davis N, Andreou P, Wells P, Kovacs M, Rodger MA, Ramsay T, Carrier M, Vendittoli PA. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med. 2013 Jun 4;158(11):800-6. [http://annals.org/aim/fullarticle/1692573/aspirin-versus-low-molecular-weight-heparin-extended-venous-thromboembolism-prophylaxis link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23732713 PubMed]
# '''EPCAT II:''' Anderson DR, Dunbar M, Murnaghan J, Kahn SR, Gross P, Forsythe M, Pelet S, Fisher W, Belzile E, Dolan S, Crowther M, Bohm E, MacDonald SJ, Gofton W, Kim P, Zukor D, Pleasance S, Andreou P, Doucette S, Theriault C, Abianui A, Carrier M, Kovacs MJ, Rodger MA, Coyle D, Wells PS, Vendittoli PA. Aspirin or rivaroxaban for VTE prophylaxis after hip or knee arthroplasty. N Engl J Med. 2018 Feb 22;378(8):699-707. [https://www.nejm.org/doi/full/10.1056/NEJMoa1712746 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29466159 PubMed]

==Betrixaban monotherapy {{#subobject:834d5c|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:f70ffb|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1601747 Cohen et al. 2016 (APEX-VTE)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Enoxaparin_monotherapy|Enoxaparin]]
| style="background-color:#d9ef8b" |Might have lower rates of VTE
|-
|}
''Note: this APEX trial should not be confused with the one in multiple myeloma.''
====Anticoagulation====
*[[Betrixaban (Bevyxxa)]] 80 mg PO once per day
===References===
# '''APEX:''' Cohen AT, Harrington RA, Goldhaber SZ, Hull RD, Wiens BL, Gold A, Hernandez AF, Gibson CM; APEX Investigators. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med. 2016 Aug 11;375(6):534-44. Epub 2016 May 27. [https://www.nejm.org/doi/full/10.1056/NEJMoa1601747 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27232649 PubMed]

==Enoxaparin monotherapy {{#subobject:f7bdac|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 30 mg every 12 hours {{#subobject:a4d4d8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 20%" |Study
! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 20%" |Comparator
! style="width: 20%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
! style="width: 20%" |[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM199609053351003 Geerts et al. 1996] 
| style="background-color:#1a9851" |Phase III (E)
|Heparin
| style="background-color:#1a9850" |Superior DVT rates
| style="background-color:#ffffbf" |No difference in major bleeding rate
|-
|[https://www.nejm.org/doi/10.1056/NEJMoa0810773 Lassen et al. 2009 (ADVANCE-1)]]
| style="background-color:#1a9851" |Phase III (C)
|[[#Apixaban_monotherapy|Apixaban]]
| style="background-color:#ffffbf" |Seems not superior
| style="background-color:#fc8d59" |Seems to have higher bleeding rate
|}
====Preceding treatment====
*Total knee replacement (ADVANCE-1)
*The study population in Geerts et. al. were trauma patients without intracranial hemorrhage. Prophylaxis was initiated within 36 hours of the injury.
====Anticoagulation====
*[[Enoxaparin (Lovenox)]] 30 mg SC every 12 hours, beginning 12 to 24 h after wound closure (ADVANCE-1), 10- to 14-day course 
*The comparison arm in Geerts et al. used heparin 5000 units subcutaneous every 12 hours.  

===Variant #2, 40 mg daily {{#subobject:8e940e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)60880-6/fulltext Kakkar et al. 2008 (RECORD2)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Rivaroxaban_monotherapy|Rivaroxaban]]
| style="background-color:#d73027" |Inferior composite outcome
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa0800374 Erikkson et al. 2008 (RECORD1)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Rivaroxaban_monotherapy|Rivaroxaban]]
| style="background-color:#d73027" |Inferior composite outcome
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa076016 Lassen et al. 2008 (RECORD3)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Rivaroxaban_monotherapy|Rivaroxaban]]
| style="background-color:#d73027" |Inferior composite outcome
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)60734-0/fulltext Turpie et al. 2009 (RECORD4)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Rivaroxaban_monotherapy|Rivaroxaban]]
| style="background-color:#fc8d59" |Seems to have inferior composite outcome
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)62125-5/fulltext Lassen et al. 2010 (ADVANCE-2)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Apixaban_monotherapy|Apixaban]]
| style="background-color:#d73027" |Inferior composite outcome
|-
|[http://annals.org/aim/fullarticle/745859/extended-duration-venous-thromboembolism-prophylaxis-acutely-ill-medical-patients-recently Hull et al. 2010 (EXCLAIM)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Placebo|Placebo]]
| style="background-color:#1a9850" |Superior composite VTE rate
|-
|[https://www.nejm.org/doi/10.1056/NEJMoa1006885 Lassen et al. 2010 (ADVANCE-3)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Apixaban_monotherapy|Apixaban]]
| style="background-color:#d73027" |Inferior composite outcome
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.31.6844 Palumbo et al. 2011]
| style="background-color:#1a9851" |Phase III (E)
|1. [[#Aspirin_monotherapy|Aspirin]]<br> 2. Low-dose warfarin
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://www.bloodjournal.org/content/119/4/933.long Larocca et al. 2011]
| style="background-color:#1a9851" |Phase III (E)
|[[#Aspirin_monotherapy|Aspirin]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.nejm.org/doi/10.1056/NEJMoa1110899 Goldhaber et al. 2011 (ADOPT)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Apixaban_monotherapy|Apixaban]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.nejm.org/doi/10.1056/NEJMoa1111288 Kakkar et al. 2011 (LIFENOX)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Placebo|Placebo]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1111096 Cohen et al. 2013 (MAGELLAN)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Rivaroxaban_monotherapy|Rivaroxaban]]
| style="background-color:#eeee01" |Non-inferior VTE rate at 10 days
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1601747 Cohen et al. 2016 (APEX-VTE)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Betrixaban_monotherapy|Betrixaban]]
| style="background-color:#fee08b" |Might have higher rates of VTE
|-
|}
''Note: the APEX trial here should not be confused with the one in multiple myeloma.''
====Preceding treatment====
*ADVANCE-2: Total knee replacement
*ADVANCE-3: Total hip replacement
====Anticoagulation====
*[[Enoxaparin (Lovenox)]] 40 mg SC once per day

'''Various durations (see papers for details)'''
===References===
# Geerts WH, Richard MJ, Code KI, Chen E, Szalai JP, Saibil EA, and Hamilton PH. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med. 1996; 335:701-707. [https://www.nejm.org/doi/full/10.1056/NEJM199609053351003 link to original article]. [https://www.ncbi.nlm.nih.gov/pubmed/8703169 PubMed].
# '''RECORD2:''' Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008 Jul 5;372(9632):31-9. Epub 2008 Jun 24. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)60880-6/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18582928 PubMed]
# '''RECORD1:''' Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008 Jun 26;358(26):2765-75. [https://www.nejm.org/doi/full/10.1056/NEJMoa0800374 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18579811 PubMed]
# '''RECORD3:''' Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008 Jun 26;358(26):2776-86. [https://www.nejm.org/doi/full/10.1056/NEJMoa076016 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18579812 PubMed]
# '''RECORD4:''' Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD; RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009 May 16;373(9676):1673-80. Epub 2009 May 4. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)60734-0/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19411100 PubMed]
# '''ADVANCE-1:''' Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009 Aug 6;361(6):594-604. Erratum in: N Engl J Med. 2009 Oct 29;361(18):1814. [https://www.nejm.org/doi/10.1056/NEJMoa0810773 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19657123 PubMed]
# '''ADVANCE-2:''' Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P; ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010 Mar 6;375(9717):807-15. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)62125-5/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20206776 PubMed]
# '''EXCLAIM:''' Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Nicol P, Vicaut E, Turpie AG, Yusen RD; EXCLAIM (Extended Prophylaxis for Venous ThromboEmbolism in Acutely Ill Medical Patients With Prolonged Immobilization) study. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med. 2010 Jul 6;153(1):8-18. [http://annals.org/aim/fullarticle/745859/extended-duration-venous-thromboembolism-prophylaxis-acutely-ill-medical-patients-recently link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/20621900 PubMed]
# '''ADVANCE-3:''' Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM; ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010 Dec 23;363(26):2487-98. [https://www.nejm.org/doi/10.1056/NEJMoa1006885 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21175312 PubMed]
# Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F, Rossi D, Gentilini F, Crippa C, Galli M, Nozzoli C, Ria R, Marasca R, Montefusco V, Baldini L, Elice F, Callea V, Pulini S, Carella AM, Zambello R, Benevolo G, Magarotto V, Tacchetti P, Pescosta N, Cellini C, Polloni C, Evangelista A, Caravita T, Morabito F, Offidani M, Tosi P, Boccadoro M. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol. 2011 Mar 10;29(8):986-93. Epub 2011 Jan 31. [http://ascopubs.org/doi/full/10.1200/JCO.2010.31.6844 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21282540 PubMed]
# Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A, Cavalli M, Stanevsky A, Corradini P, Pezzatti S, Patriarca F, Cavo M, Peccatori J, Catalano L, Carella AM, Cafro AM, Siniscalchi A, Crippa C, Petrucci MT, Yehuda DB, Beggiato E, Di Toritto TC, Boccadoro M, Nagler A, Palumbo A. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood. 2012 Jan 26;119(4):933-9. Epub 2011 Aug 11. [http://www.bloodjournal.org/content/119/4/933.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21835953 PubMed]
# '''ADOPT:''' Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM, Weitz JI; ADOPT Trial Investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011 Dec 8;365(23):2167-77. Epub 2011 Nov 13. [https://www.nejm.org/doi/10.1056/NEJMoa1110899 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22077144 PubMed]
# '''LIFENOX:''' Kakkar AK, Cimminiello C, Goldhaber SZ, Parakh R, Wang C, Bergmann JF; LIFENOX Investigators. Low-molecular-weight heparin and mortality in acutely ill medical patients. N Engl J Med. 2011 Dec 29;365(26):2463-72. [https://www.nejm.org/doi/10.1056/NEJMoa1111288 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22204723 PubMed]
# '''MAGELLAN:''' Cohen AT, Spiro TE, B√ºller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos AC, Tapson V; MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013 Feb 7;368(6):513-23. [https://www.nejm.org/doi/full/10.1056/NEJMoa1111096 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23388003 PubMed]
# '''APEX:''' Cohen AT, Harrington RA, Goldhaber SZ, Hull RD, Wiens BL, Gold A, Hernandez AF, Gibson CM; APEX Investigators. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med. 2016 Aug 11;375(6):534-44. Epub 2016 May 27. [https://www.nejm.org/doi/full/10.1056/NEJMoa1601747 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27232649 PubMed]

==Placebo==
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.sciencedirect.com/science/article/pii/S0140673696910090 G√§rdlund et al. 1996]
| style="background-color:#1a9851" |Phase III (C)
|Heparin (SC)
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://annals.org/aim/fullarticle/745859/extended-duration-venous-thromboembolism-prophylaxis-acutely-ill-medical-patients-recently Hull et al. 2010 (EXCLAIM)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Enoxaparin_monotherapy|Enoxaparin]]
| style="background-color:#d73027" |Inferior composite VTE rate
|-
|[https://www.nejm.org/doi/10.1056/NEJMoa1111288 Kakkar et al. 2011 (LIFENOX)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Enoxaparin_monotherapy|Enoxaparin]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.nejm.org/doi/10.1056/NEJMoa1805090 Spyropoulos et al. 2018 (MARINER)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Rivaroxaban_monotherapy|Rivaroxaban]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''No active treatment.''
===References===
# G√§rdlund B; The Heparin Prophylaxis Study Group. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. Lancet. 1996 May 18;347(9012):1357-61. [https://www.sciencedirect.com/science/article/pii/S0140673696910090 link to SD article] [https://www.ncbi.nlm.nih.gov/pubmed/8637340 PubMed]
# '''EXCLAIM:''' Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Nicol P, Vicaut E, Turpie AG, Yusen RD; EXCLAIM (Extended Prophylaxis for Venous ThromboEmbolism in Acutely Ill Medical Patients With Prolonged Immobilization) study. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med. 2010 Jul 6;153(1):8-18. [http://annals.org/aim/fullarticle/745859/extended-duration-venous-thromboembolism-prophylaxis-acutely-ill-medical-patients-recently link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/20621900 PubMed]
# '''LIFENOX:''' Kakkar AK, Cimminiello C, Goldhaber SZ, Parakh R, Wang C, Bergmann JF; LIFENOX Investigators. Low-molecular-weight heparin and mortality in acutely ill medical patients. N Engl J Med. 2011 Dec 29;365(26):2463-72. [https://www.nejm.org/doi/10.1056/NEJMoa1111288 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22204723 PubMed]
# '''MARINER:''' Spyropoulos AC, Ageno W, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard GA, Steg PG, Weitz JI, Suh E, Spiro TE, Barnathan ES, Raskob GE; MARINER Investigators. Rivaroxaban for thromboprophylaxis after hospitalization for medical illness. N Engl J Med. 2018 Sep 20;379(12):1118-1127. Epub 2018 Aug 26. [https://www.nejm.org/doi/10.1056/NEJMoa1805090 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30145946 PubMed]

==Rivaroxaban monotherapy {{#subobject:6a7fba|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:828315|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)60880-6/fulltext Kakkar et al. 2008 (RECORD2)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Enoxaparin_monotherapy|Enoxaparin]]
| style="background-color:#1a9850" |Superior composite outcome
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa0800374 Erikkson et al. 2008 (RECORD1)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Enoxaparin_monotherapy|Enoxaparin]]
| style="background-color:#1a9850" |Superior composite outcome
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa076016 Lassen et al. 2008 (RECORD3)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Enoxaparin_monotherapy|Enoxaparin]]
| style="background-color:#1a9850" |Superior composite outcome
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)60734-0/fulltext Turpie et al. 2009 (RECORD4)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Enoxaparin_monotherapy|Enoxaparin]]
| style="background-color:#91cf60" |Seems to have superior composite outcome
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1111096 Cohen et al. 2013 (MAGELLAN)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Enoxaparin_monotherapy|Enoxaparin]]
| style="background-color:#eeee01" |Non-inferior VTE rate at 10 days
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1712746 Anderson et al. 2018 (EPCAT II)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Aspirin_monotherapy|Aspirin]]
| style="background-color:#eeee01" |Non-inferior VTE rate at 90 days
|-
|[https://www.nejm.org/doi/10.1056/NEJMoa1805090 Spyropoulos et al. 2018 (MARINER)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Placebo|Placebo]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Anticoagulation====
*[[Rivaroxaban (Xarelto)]] 10 mg PO once per day for varying durations (see individual studies)
===References===
# '''RECORD2:''' Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008 Jul 5;372(9632):31-9. Epub 2008 Jun 24. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)60880-6/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18582928 PubMed]
# '''RECORD1:''' Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008 Jun 26;358(26):2765-75. [https://www.nejm.org/doi/full/10.1056/NEJMoa0800374 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18579811 PubMed]
# '''RECORD3:''' Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008 Jun 26;358(26):2776-86. [https://www.nejm.org/doi/full/10.1056/NEJMoa076016 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18579812 PubMed]
# '''RECORD4:''' Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD; RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009 May 16;373(9676):1673-80. Epub 2009 May 4. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)60734-0/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19411100 PubMed]
# '''MAGELLAN:''' Cohen AT, Spiro TE, B√ºller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos AC, Tapson V; MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013 Feb 7;368(6):513-23. [https://www.nejm.org/doi/full/10.1056/NEJMoa1111096 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23388003 PubMed]
# '''EPCAT II:''' Anderson DR, Dunbar M, Murnaghan J, Kahn SR, Gross P, Forsythe M, Pelet S, Fisher W, Belzile E, Dolan S, Crowther M, Bohm E, MacDonald SJ, Gofton W, Kim P, Zukor D, Pleasance S, Andreou P, Doucette S, Theriault C, Abianui A, Carrier M, Kovacs MJ, Rodger MA, Coyle D, Wells PS, Vendittoli PA. Aspirin or rivaroxaban for VTE prophylaxis after hip or knee arthroplasty. N Engl J Med. 2018 Feb 22;378(8):699-707. [https://www.nejm.org/doi/full/10.1056/NEJMoa1712746 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29466159 PubMed]
# '''MARINER:''' Spyropoulos AC, Ageno W, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard GA, Steg PG, Weitz JI, Suh E, Spiro TE, Barnathan ES, Raskob GE; MARINER Investigators. Rivaroxaban for thromboprophylaxis after hospitalization for medical illness. N Engl J Med. 2018 Sep 20;379(12):1118-1127. Epub 2018 Aug 26. [https://www.nejm.org/doi/10.1056/NEJMoa1805090 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30145946 PubMed]

=VTE secondary prevention=
==Apixaban monotherapy {{#subobject:94eb02|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 2.5 mg twice per day {{#subobject:969d50|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;"
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
!Comparator
![[Levels_of_Evidence#Efficacy|Efficacy]]
|-
| rowspan="2" |[https://www.nejm.org/doi/full/10.1056/NEJMoa1207541 Agnelli et al. 2012 (AMPLIFY-EXT)]
| rowspan="2" style="background-color:#1a9851" |Phase III (E)
|1. Apixaban 5 mg twice per day
| style="background-color:#ffffbf" |Seems not superior
|-
|2. Placebo
| style="background-color:#1a9850" |Superior composite endpoint
|-
|}
====Preceding treatment====
*Therapeutic anticoagulation x 6-12 mo
====Anticoagulation====
*[[Apixaban (Eliquis)]] 2.5 mg PO twice per day

'''12-month course'''

===Variant #2, 5 mg twice per day {{#subobject:c7bfff0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;"
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
!Comparator
![[Levels_of_Evidence#Efficacy|Efficacy]]
|-
| rowspan="2" |[https://www.nejm.org/doi/full/10.1056/NEJMoa1207541 Agnelli et al. 2012 (AMPLIFY-EXT)]
| rowspan="2" style="background-color:#1a9851" |Phase III (E)
|1. Apixaban 2.5 mg twice per day
| style="background-color:#ffffbf" |Seems not superior
|-
|2. Placebo
| style="background-color:#1a9850" |Superior composite endpoint
|-
|}
====Preceding treatment====
*Therapeutic anticoagulation x 6-12 mo
====Anticoagulation====
*[[Apixaban (Eliquis)]] 5 mg PO twice per day

'''12-month course'''

===References===
# '''AMPLIFY-EXT:''' Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013 Feb 21;368(8):699-708. Epub 2012 Dec 8. [https://www.nejm.org/doi/full/10.1056/NEJMoa1207541 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23216615 PubMed]

==Aspirin monotherapy {{#subobject:eb5633|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:e3079b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 20%" |Study
! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 20%" |Comparator
! style="width: 20%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
! style="width: 20%" |[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1114238 Becattini et al. 2012 (WARFASA)]
| style="background-color:#1a9851" |Phase III (E)
|Placebo
| style="background-color:#1a9850" |Superior rate of VTE recurrence
| style="background-color:#ffffbf" |No difference in bleeding rate
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1210384 Brighton et al. 2012 (ASPIRE-VTE)]
| style="background-color:#1a9851" |Phase III (E)
|Placebo
| style="background-color:#d9ef8b" |Might have superior rate of VTE recurrence
| style="background-color:#ffffbf" |No difference in bleeding rate
|-
|}
''Note: ASPIRE should not be confused with the multiple myeloma trial of the same name.''
====Preceding treatment====
*WARFASA: [[#Warfarin_monotherapy|Warfarin]] x 6 to 18 months
*ASPIRE: [[#Warfarin_monotherapy|Warfarin]] x 6 weeks to 24 months
====Anticoagulation====
*[[Aspirin]] 100 mg PO once per day

'''Two or more years'''

===References===
# '''WARFASA:''' Becattini C, Agnelli G, Schenone A, Eichinger S, Bucherini E, Silingardi M, Bianchi M, Moia M, Ageno W, Vandelli MR, Grandone E, Prandoni P; WARFASA Investigators. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med. 2012 May 24;366(21):1959-67. Erratum in: N Engl J Med. 2012 Oct 18;367(16):1573. [https://www.nejm.org/doi/full/10.1056/NEJMoa1114238 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22621626 PubMed]
# '''ASPIRE:''' Brighton TA, Eikelboom JW, Mann K, Mister R, Gallus A, Ockelford P, Gibbs H, Hague W, Xavier D, Diaz R, Kirby A, Simes J; ASPIRE Investigators. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med. 2012 Nov 22;367(21):1979-87. Epub 2012 Nov 4. [https://www.nejm.org/doi/full/10.1056/NEJMoa1210384 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23121403 PubMed]

==Dalteparin monotherapy {{#subobject:57c5b7|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:cbc29a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 20%" |Study
! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 20%" |Comparator
! style="width: 20%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
! style="width: 20%" |[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa025313 Lee et al. 2003 (CLOT)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Warfarin_monotherapy|Warfarin]]
| style="background-color:#1a9850" |Superior rate of VTE at 6 months
| style="background-color:#ffffbf" |No difference in bleeding rate
|-
|}
====Anticoagulation====
*[[Dalteparin (Fragmin)]] as follows:
**'''Month 1:''' 200 IU/kg SC once per day
**'''Months 2 to 6:''' 150 IU/kg SC once per day

'''6-month course'''
===References===
# '''CLOT:''' Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003 Jul 10;349(2):146-53. [https://www.nejm.org/doi/full/10.1056/NEJMoa025313 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12853587 PubMed]
## '''Posthoc analysis:''' Lee AY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, Kakkar AK, Prins M, Levine MN. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol. 2005 Apr 1;23(10):2123-9. Epub 2005 Feb 7. [http://jco.ascopubs.org/content/23/10/2123.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15699480 PubMed]

==Enoxaparin monotherapy {{#subobject:30d50d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:a64a42|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://archinte.jamanetwork.com/article.aspx?articleid=754085 Meyer et al. 2002]
| style="background-color:#1a9851" |Phase III (E)
|[[#Warfarin_monotherapy|Warfarin]]
| style="background-color:#d9ef8b" |Might have superior combined VTE/bleeding outcome
|-
|}
====Anticoagulation====
*[[Enoxaparin (Lovenox)]] 1.5 mg/kg SC once per day

'''3-month course'''
===References===
# Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, Le Maignan C, Extra JM, Cottu P, Farge D. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002 Aug 12-26;162(15):1729-35. [http://archinte.jamanetwork.com/article.aspx?articleid=754085 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12153376 PubMed]

==Warfarin monotherapy {{#subobject:acc688|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, standard intensity {{#subobject:3eda79|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 20%" |Study
! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 20%" |Comparator
! style="width: 20%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
! style="width: 20%" |[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[http://archinte.jamanetwork.com/article.aspx?articleid=754085 Meyer et al. 2002]
| style="background-color:#1a9851" |Phase III (C)
|[[#Enoxaparin_monotherapy_2|Enoxaparin]]
| style="background-color:#fee08b" |Might have inferior combined VTE/bleeding outcome
|
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa025313 Lee et al. 2003 (CLOT)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Dalteparin_monotherapy|Dalteparin]]
| style="background-color:#d73027" |Inferior rate of VTE at 6 months
| style="background-color:#ffffbf" |No difference in bleeding rate
|-
|}
====Anticoagulation====
*[[Warfarin (Coumadin)]] PO titrated to goal INR 2.0 to 3.0

===Variant #2, low intensity {{#subobject:7c40af|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 20%" |Study
! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 20%" |Comparator
! style="width: 20%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
! style="width: 20%" |[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa035029 Ridker et al. 2003 (PREVENT)]
| style="background-color:#1a9851" |Phase III (E)
|Placebo
| style="background-color:#1a9850" |Superior recurrent VTE rate
| style="background-color:#ffffbf" |No difference in major bleeding
|-
|}
====Preceding treatment====
*Warfarin with goal INR of 2.0 to 3.0 for median of 6.5 mo
====Anticoagulation====
*[[Warfarin (Coumadin)]] PO titrated to goal INR 1.5 to 2.0

'''Continued indefinitely'''

===References===
# Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, Le Maignan C, Extra JM, Cottu P, Farge D. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002 Aug 12-26;162(15):1729-35. [http://archinte.jamanetwork.com/article.aspx?articleid=754085 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12153376 PubMed]
# '''PREVENT:''' Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, Cushman M, Moll S, Kessler CM, Elliott CG, Paulson R, Wong T, Bauer KA, Schwartz BA, Miletich JP, Bounameaux H, Glynn RJ; PREVENT Investigators. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003 Apr 10;348(15):1425-34. Epub 2003 Feb 24. [https://www.nejm.org/doi/full/10.1056/NEJMoa035029 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12601075 PubMed]
# '''CLOT:''' Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003 Jul 10;349(2):146-53. [https://www.nejm.org/doi/full/10.1056/NEJMoa025313 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12853587 PubMed]
## '''Posthoc analysis:''' Lee AY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, Kakkar AK, Prins M, Levine MN. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol. 2005 Apr 1;23(10):2123-9. Epub 2005 Feb 7. [http://jco.ascopubs.org/content/23/10/2123.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15699480 PubMed]

=VTE treatment, all lines of therapy=
==Apixaban monotherapy {{#subobject:f80057|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:856942|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;"
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
!Comparator
![[Levels_of_Evidence#Efficacy|Efficacy]]
![[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1302507 Agnelli et al. 2013 (AMPLIFY)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Warfarin_monotherapy_2|Warfarin]]
| style="background-color:#eeee01" |Non-inferior composite endpoint
| style="background-color:#1a9850" |Lower rates of bleeding
|-
|}
====Anticoagulation====
*[[Apixaban (Eliquis)]] 10 mg PO twice per day for 7 days, then 5 mg PO twice per day

'''6-month course'''

===References===
# '''AMPLIFY:''' Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013 Aug 29;369(9):799-808. Epub 2013 Jul 1. [https://www.nejm.org/doi/full/10.1056/NEJMoa1302507 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23808982 PubMed]

==Argatroban monotherapy {{#subobject:8171b3|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:3f6d7f|Variant=1}}===
====Anticoagulation====
*[[Argatroban (Acova)]]
===References===
To be completed

==Aspirin monotherapy {{#subobject:0481f0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:0113df|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;"
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
!Comparator
![[Levels_of_Evidence#Efficacy|Efficacy]]
![[Levels_of_Evidence#Toxicity|Toxicity]]
|-
| rowspan="2" |[https://www.nejm.org/doi/full/10.1056/NEJMoa1700518 Weitz et al. 2017 (EINSTEIN CHOICE)]
| rowspan="2" style="background-color:#1a9851" |Phase III (C)
|1. [[#Rivaroxaban_monotherapy_2|Rivaroxaban 10 mg]]
| style="background-color:#d73027" |Inferior symptomatic recurrent VTE rate
| style="background-color:#ffffbf" |Similar major bleeding
|-
|2. [[#Rivaroxaban_monotherapy_2|Rivaroxaban 20 mg]]
| style="background-color:#d73027" |Inferior symptomatic recurrent VTE rate
| style="background-color:#ffffbf" |Similar major bleeding
|-
|}
====Preceding treatment====
*6 to 12 months of a vitamin K antagonist or a direct oral anticoagulant

====Anticoagulation====
*[[Aspirin]] 100 mg PO once per day 

'''Up to 12-month course'''
===References===
# '''EINSTEIN CHOICE:''' Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Freitas MCS, Holberg G, Kakkar AK, Haskell L, van Bellen B, Pap AF, Berkowitz SD, Verhamme P, Wells PS, Prandoni P; EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med. 2017 Mar 30;376(13):1211-1222. Epub 2017 Mar 18. [https://www.nejm.org/doi/full/10.1056/NEJMoa1700518 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28316279 PubMed]

==Bivalirudin monotherapy {{#subobject:5a08f6|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:5faf02|Variant=1}}===
====Anticoagulation====
*[[Bivalirudin (Angiomax)]]
===References===
To be completed
==Dabigatran monotherapy {{#subobject:4b48cf|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:518855|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;"
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
!Comparator
![[Levels_of_Evidence#Efficacy|Efficacy]]
![[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa0906598 Schulman et al. 2009 (RE-COVER)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Warfarin_monotherapy_2|Warfarin]]
| style="background-color:#eeee01" |Non-inferior composite endpoint
| style="background-color:#ffffbf" |Similar major bleeding
|-
|}
====Anticoagulation====
*[[Dabigatran (Pradaxa)]] 150 mg PO twice per day

'''6-month course'''
===References===
# '''RE-COVER:''' Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009 Dec 10;361(24):2342-52. [https://www.nejm.org/doi/full/10.1056/NEJMoa0906598 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19966341 PubMed]
# '''RE-MEDY:''' Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, Kvamme AM, Friedman J, Mismetti P, Goldhaber SZ; RE-MEDY Trial Investigators; RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013 Feb 21;368(8):709-18. [https://www.nejm.org/doi/full/10.1056/NEJMoa1113697 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23425163 PubMed]
# '''RE-COVER II:''' Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, Christiansen AV, Friedman J, Le Maulf F, Peter N, Kearon C; RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014 Feb 18;129(7):764-72. Epub 2013 Dec 16. [http://circ.ahajournals.org/content/129/7/764.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24344086 PubMed]

==Dalteparin monotherapy {{#subobject:4a96a1|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:afbbc0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 20%" |Study
! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 20%" |Comparator
! style="width: 20%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
! style="width: 20%" |[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/jth.12923/abstract Francis et al. 2015 (DALTECAN)]
| style="background-color:#1a9851" |Non-randomized
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1711948 Raskob et al. 2017 (Hokusai VTE Cancer)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Edoxaban_monotherapy|Edoxaban]]
| style="background-color:#eeee01" |Non-inferior composite endpoint of VTE/major bleeding
| style="background-color:#eeee01" |Non-inferior composite endpoint of VTE/major bleeding
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2018.78.8034 Young et al. 2018 (SELECT-D)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Rivaroxaban_monotherapy_2|Rivaroxaban]]
| style="background-color:#fc8d59" |Seems to have inferior rate of VTE recurrence
| style="background-color:#1a9850" |Superior rates of clinically relevant non-major bleeding
|-
|}
====Anticoagulation====
*[[Dalteparin (Fragmin)]] as follows:
**First month: 200 IU/kg once per day
**Subsequent months: 150 IU/kg once per day

'''6- to 12-month course'''
===References===
# '''DALTECAN:''' Francis CW, Kessler CM, Goldhaber SZ, Kovacs MJ, Monreal M, Huisman MV, Bergqvist D, Turpie AG, Ortel TL, Spyropoulos AC, Pabinger I, Kakkar AK. Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. J Thromb Haemost. 2015 Jun;13(6):1028-35. Epub 2015 May 10. [https://onlinelibrary.wiley.com/doi/10.1111/jth.12923/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25827941 PubMed]
# '''Hokusai VTE Cancer:''' Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri MF, Meyer G, Segers A, Shi M, Wang TF, Yeo E, Zhang G, Zwicker JI, Weitz JI, B√ºller HR; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018 Feb 15;378(7):615-624. Epub 2017 Dec 12. [https://www.nejm.org/doi/full/10.1056/NEJMoa1711948 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29231094 PubMed]
# '''SELECT-D:''' Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, Hale D, Dunn JA, Lyman GH, Hutchinson C, MacCallum P, Kakkar A, Hobbs FDR, Petrou S, Dale J, Poole CJ, Maraveyas A, Levine M. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018 Jul 10;36(20):2017-2023. Epub 2018 May 10. [http://ascopubs.org/doi/full/10.1200/JCO.2018.78.8034 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29746227 PubMed]

==Edoxaban monotherapy {{#subobject:d0ebe7|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, reduced dose {{#subobject:5c53d8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;"
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
!Comparator
![[Levels_of_Evidence#Efficacy|Efficacy]]
![[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1306638 B√ºller et al. 2013 (Hokusai-VTE)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Warfarin_monotherapy_2|Warfarin]]
| style="background-color:#eeee01" |Non-inferior recurrent VTE rate
| style="background-color:#1a9850" |Superior rate of bleeding
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1711948 Raskob et al. 2017 (Hokusai VTE Cancer)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Dalteparin_monotherapy_2|Dalteparin]]
| style="background-color:#eeee01" |Non-inferior composite endpoint of VTE/major bleeding
| style="background-color:#eeee01" |Non-inferior composite endpoint of VTE/major bleeding
|-
|}
''Note: this dose was used for patients with CrCl of 30 to 50 mL/min/1.73m<sup>2</sup>, a body weight of up to 60 kg, or those taking "potent" [[P-glycoprotein_modifying_drugs#P-glycoprotein_inhibitors|P-glycoprotein inhibitors]].''
====Anticoagulation====
*Therapeutic dose [[:Category:Low molecular weight heparins|LMWH]] for at least 5 days, then:
*[[Edoxaban (Savaysa)]] 30 mg PO once per day

'''3- to 12-month course'''

===Variant #2, normal dosing {{#subobject:88a424|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;"
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
!Comparator
![[Levels_of_Evidence#Efficacy|Efficacy]]
![[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1306638 B√ºller et al. 2013 (Hokusai-VTE)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Warfarin_monotherapy_2|Warfarin]]
| style="background-color:#eeee01" |Non-inferior recurrent VTE rate
| style="background-color:#1a9850" |Lower rates of bleeding
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1711948 Raskob et al. 2017 (Hokusai VTE Cancer)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Dalteparin_monotherapy_2|Dalteparin]]
| style="background-color:#eeee01" |Non-inferior composite endpoint of VTE/major bleeding
| style="background-color:#eeee01" |Non-inferior composite endpoint of VTE/major bleeding
|-
|}
====Anticoagulation====
*Therapeutic dose [[:Category:Low molecular weight heparins|LMWH]] for at least 5 days, then:
*[[Edoxaban (Savaysa)]] 60 mg PO once per day

'''3- to 12-month course'''
===References===
# '''Hokusai-VTE:''' B√ºller HR, D√©cousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P; Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013 Oct 10;369(15):1406-15. Epub 2013 Aug 31. Erratum in: N Engl J Med. 2014 Jan 23;370(4):390. [https://www.nejm.org/doi/full/10.1056/NEJMoa1306638 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23991658 PubMed]
## '''Subgroup analysis:''' Raskob GE, van Es N, Segers A, Angchaisuksiri P, Oh D, Boda Z, Lyons RM, Meijer K, Gudz I, Weitz JI, Zhang G, Lanz H, Mercuri MF, B√ºller HR; Hokusai-VTE investigators. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol. 2016 Aug;3(8):e379-87. Epub 2016 Jul 1. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30057-6/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27476789 PubMed]
# '''Hokusai VTE Cancer:''' Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri MF, Meyer G, Segers A, Shi M, Wang TF, Yeo E, Zhang G, Zwicker JI, Weitz JI, B√ºller HR; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018 Feb 15;378(7):615-624. Epub 2017 Dec 12. [https://www.nejm.org/doi/full/10.1056/NEJMoa1711948 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29231094 PubMed]

==Enoxaparin monotherapy {{#subobject:fc9e30|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:5a4974|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://jamanetwork.com/journals/jama/fullarticle/203221 Kearon et al. 2006 (FIDO)]
| style="background-color:#1a9851" |Phase III (E)
|1. [[#Dalteparin_monotherapy_2|Dalteparin]]<br> 2. [[#Heparin_monotherapy|Heparin]]
| style="background-color:#eeee01" |No difference in recurrent VTE or major bleeding
|}

====Anticoagulation====
*[[Enoxaparin (Lovenox)]]
===References===
# '''FIDO:''' Kearon C, Ginsberg JS, Julian JA, Douketis J, Solymoss S, Ockelford P, Jackson S, Turpie AG, MacKinnon B, Hirsh J, Gent M; Fixed-Dose Heparin (FIDO) Investigators. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA. 2006 Aug23;296(8):935-42. [https://jamanetwork.com/journals/jama/fullarticle/203221 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16926353 PubMed]

==Fondaparinux monotherapy {{#subobject:7a8cb8|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:ab5c25|Variant=1}}===
====Anticoagulation====
*[[Fondaparinux (Arixtra)]]
===References===
To be completed

==Heparin monotherapy {{#subobject:2a8be8|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:8cae03|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://jamanetwork.com/journals/jama/fullarticle/203221 Kearon et al. 2006 (FIDO)]
| style="background-color:#1a9851" |Phase III (C)
|1. [[#Dalteparin_monotherapy_2|Dalteparin]]<br> 2. [[#Enoxaparin_monotherapy_3|Enoxaparin]]
| style="background-color:#eeee01" |No difference in recurrent VTE or major bleeding
|}

====Anticoagulation====
*[[Heparin]] administered subcutaneously, initial dose 333 U/kg, followed by a fixed dose of 250 U/kg every 12 hours
===References===
# '''FIDO:''' Kearon C, Ginsberg JS, Julian JA, Douketis J, Solymoss S, Ockelford P, Jackson S, Turpie AG, MacKinnon B, Hirsh J, Gent M; Fixed-Dose Heparin (FIDO) Investigators. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA. 2006 Aug23;296(8):935-42. [https://jamanetwork.com/journals/jama/fullarticle/203221 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16926353 PubMed]

==Lepirudin monotherapy {{#subobject:b61e00|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:22918f|Variant=1}}===
====Anticoagulation====
*[[Lepirudin (Refludan)]]
===References===
To be completed

==Rivaroxaban monotherapy {{#subobject:f435a7|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 10 mg/day {{#subobject:4f1fdf|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;"
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
!Comparator
![[Levels_of_Evidence#Efficacy|Efficacy]]
![[Levels_of_Evidence#Toxicity|Toxicity]]
|-
| rowspan="2" |[https://www.nejm.org/doi/full/10.1056/NEJMoa1700518 Weitz et al. 2017 (EINSTEIN CHOICE)]
| rowspan="2" style="background-color:#1a9851" |Phase III (E)
|1. [[#Aspirin_monotherapy_2|Aspirin]]
| style="background-color:#1a9850" |Superior symptomatic recurrent VTE rate
| style="background-color:#ffffbf" |Similar major bleeding
|-
|2. Rivaroxaban 20 mg
| style="background-color:#ffffbf" |Seems not superior
| style="background-color:#ffffbf" |Similar major bleeding
|-
|}
====Preceding treatment====
*6 to 12 months of a vitamin K antagonist or a direct oral anticoagulant
====Anticoagulation====
*[[Rivaroxaban (Xarelto)]] 10 mg PO once per day

'''Up to 12-month course'''

===Variant #2, 20 mg/day {{#subobject:ba11d9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;"
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
!Comparator
![[Levels_of_Evidence#Efficacy|Efficacy]]
![[Levels_of_Evidence#Toxicity|Toxicity]]
|-
| rowspan="2" |[https://www.nejm.org/doi/full/10.1056/NEJMoa1700518 Weitz et al. 2017 (EINSTEIN CHOICE)]
| rowspan="2" style="background-color:#1a9851" |Phase III (E)
|1. [[#Aspirin_monotherapy_2|Aspirin]]
| style="background-color:#1a9850" |Superior symptomatic recurrent VTE rate
| style="background-color:#ffffbf" |Similar major bleeding
|-
|2. Rivaroxaban 10 mg
| style="background-color:#ffffbf" |Seems not superior
| style="background-color:#ffffbf" |Similar major bleeding
|-
|}
====Preceding treatment====
*6 to 12 months of a vitamin K antagonist or a direct oral anticoagulant
====Anticoagulation====
*[[Rivaroxaban (Xarelto)]] 20 mg PO once per day

'''Up to 12-month course'''

===Variant #3, 20 mg/day with loading dose {{#subobject:ba11d9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;"
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
!Comparator
![[Levels_of_Evidence#Efficacy|Efficacy]]
![[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1007903 Bauersachs et al. 2010 (EINSTEIN Acute DVT)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Warfarin_monotherapy_2|Warfarin]]
| style="background-color:#eeee01" |Non-inferior VTE recurrence
| style="background-color:#ffffbf" |Similar major bleeding
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1113572 B√ºller et al. 2012 (EINSTEIN-PE)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Warfarin_monotherapy_2|Warfarin]]
| style="background-color:#eeee01" |Non-inferior symptomatic VTE recurrence
| style="background-color:#ffffbf" |Similar major bleeding
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2018.78.8034 Young et al. 2018 (SELECT-D)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Dalteparin_monotherapy_2|Dalteparin]]
| style="background-color:#91cf60" |Seems to have superior rate of VTE recurrence
| style="background-color:#d73027" |Inferior rates of clinically relevant non-major bleeding
|-
|}
====Anticoagulation====
*[[Rivaroxaban (Xarelto)]] 15 mg PO twice per day for 3 weeks, then 20 mg PO once per day

'''3-, 6-, or 12-month course'''

===References===
# '''EINSTEIN Acute DVT:''' Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010 Dec 23;363(26):2499-510. Epub 2010 Dec 3. [https://www.nejm.org/doi/full/10.1056/NEJMoa1007903 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21128814 PubMed]
# '''EINSTEIN-PE:''' B√ºller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A; EINSTEIN‚ÄìPE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012 Apr 5;366(14):1287-97. Epub 2012 Mar 26. [https://www.nejm.org/doi/full/10.1056/NEJMoa1113572 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22449293 PubMed]
# '''XALIA:''' Ageno W, Mantovani LG, Haas S, Kreutz R, Monje D, Schneider J, van Eickels M, Gebel M, Zell E, Turpie AG. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. Lancet Haematol. 2016 Jan;3(1):e12-21. Epub 2015 Dec 8. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2815%2900257-4/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26765643 PubMed]
# '''EINSTEIN CHOICE:''' Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Freitas MCS, Holberg G, Kakkar AK, Haskell L, van Bellen B, Pap AF, Berkowitz SD, Verhamme P, Wells PS, Prandoni P; EINSTEIN CHOICE Investigators. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. N Engl J Med. 2017 Mar 30;376(13):1211-1222. Epub 2017 Mar 18. [https://www.nejm.org/doi/full/10.1056/NEJMoa1700518 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28316279 PubMed]
# '''SELECT-D:''' Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, Hale D, Dunn JA, Lyman GH, Hutchinson C, MacCallum P, Kakkar A, Hobbs FDR, Petrou S, Dale J, Poole CJ, Maraveyas A, Levine M. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018 Jul 10;36(20):2017-2023. Epub 2018 May 10. [http://ascopubs.org/doi/full/10.1200/JCO.2018.78.8034 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29746227 PubMed]

==Tinzaparin monotherapy {{#subobject:3d9d84|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:24b40c|Variant=1}}===
''Note: this agent has been withdrawn from the US market.''
====Anticoagulation====
*[[Tinzaparin (Innohep)]]
===References===
# '''LITE:''' Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, Wong T, Cook R, Solymoss S, Poon MC, Raskob G; LITE Trial Investigators. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006 Dec;119(12):1062-72. [https://www.amjmed.com/article/S0002-9343(06)00263-4/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17145251 PubMed]
# '''CATCH:''' Lee AY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, Khorana AA; CATCH Investigators. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: A randomized clinical trial. JAMA. 2015 Aug 18;314(7):677-86. [http://jama.jamanetwork.com/article.aspx?articleid=2428955 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26284719 PubMed]

==Warfarin monotherapy {{#subobject:76610c|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:cd707c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;"
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
!Comparator
![[Levels_of_Evidence#Efficacy|Efficacy]]
![[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa0906598 Schulman et al. 2009 (RE-COVER)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Dabigatran_monotherapy|Dabigatran]]
| style="background-color:#eeee01" |Non-inferior composite endpoint
| style="background-color:#ffffbf" |Similar major bleeding
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1007903 Bauersachs et al. 2010 (EINSTEIN Acute DVT)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Rivaroxaban_monotherapy_2|Rivaroxaban]]
| style="background-color:#eeee01" |Non-inferior VTE recurrence
| style="background-color:#ffffbf" |Similar major bleeding
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1113572 B√ºller et al. 2012 (EINSTEIN-PE)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Rivaroxaban_monotherapy_2|Rivaroxaban]]
| style="background-color:#eeee01" |Non-inferior VTE recurrence
| style="background-color:#ffffbf" |Similar major bleeding
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1302507 Agnelli et al. 2013 (AMPLIFY)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Apixaban_monotherapy_3|Apixaban]]
| style="background-color:#eeee01" |Non-inferior composite endpoint
| style="background-color:#d73027" |Higher rates of bleeding
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1306638 B√ºller et al. 2013 (Hokusai-VTE)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Edoxaban_monotherapy|Edoxaban]]
| style="background-color:#eeee01" |Non-inferior recurrent VTE rate
| style="background-color:#d73027" |Higher rates of bleeding
|-
|}
====Anticoagulation====
*[[Warfarin (Coumadin)]] with goal INR between 2.0 and 3.0
====Supportive medications====
*Most protocols: [[Enoxaparin (Lovenox)]] 1 mg/kg SC every 12 hours until INR greater than 2.0

'''3-, 6-, or 12- month course (see individual papers)'''
===References===
# '''LITE:''' Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, Wong T, Cook R, Solymoss S, Poon MC, Raskob G; LITE Trial Investigators. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006 Dec;119(12):1062-72. [https://www.amjmed.com/article/S0002-9343(06)00263-4/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17145251 PubMed]
# '''RE-COVER:''' Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009 Dec 10;361(24):2342-52. [https://www.nejm.org/doi/full/10.1056/NEJMoa0906598 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19966341 PubMed]
# '''EINSTEIN Acute DVT:''' Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010 Dec 23;363(26):2499-510. Epub 2010 Dec 3. [https://www.nejm.org/doi/full/10.1056/NEJMoa1007903 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21128814 PubMed]
# '''EINSTEIN-PE:''' B√ºller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A; EINSTEIN‚ÄìPE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012 Apr 5;366(14):1287-97. Epub 2012 Mar 26. [https://www.nejm.org/doi/full/10.1056/NEJMoa1113572 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22449293 PubMed]
# '''RE-MEDY:''' Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, Kvamme AM, Friedman J, Mismetti P, Goldhaber SZ; RE-MEDY Trial Investigators; RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013 Feb 21;368(8):709-18. [https://www.nejm.org/doi/full/10.1056/NEJMoa1113697 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23425163 PubMed]
# '''AMPLIFY:''' Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013 Aug 29;369(9):799-808. Epub 2013 Jul 1. [https://www.nejm.org/doi/full/10.1056/NEJMoa1302507 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23808982 PubMed]
# '''Hokusai-VTE:''' B√ºller HR, D√©cousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P; Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013 Oct 10;369(15):1406-15. Epub 2013 Aug 31. Erratum in: N Engl J Med. 2014 Jan 23;370(4):390. [https://www.nejm.org/doi/full/10.1056/NEJMoa1306638 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23991658 PubMed]
## '''Subgroup analysis:''' Raskob GE, van Es N, Segers A, Angchaisuksiri P, Oh D, Boda Z, Lyons RM, Meijer K, Gudz I, Weitz JI, Zhang G, Lanz H, Mercuri MF, B√ºller HR; Hokusai-VTE investigators. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol. 2016 Aug;3(8):e379-87. Epub 2016 Jul 1. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30057-6/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27476789 PubMed]
# '''RE-COVER II:''' Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, Christiansen AV, Friedman J, Le Maulf F, Peter N, Kearon C; RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014 Feb 18;129(7):764-72. Epub 2013 Dec 16. [http://circ.ahajournals.org/content/129/7/764.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24344086 PubMed]
# '''CATCH:''' Lee AY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, Khorana AA; CATCH Investigators. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: A randomized clinical trial. JAMA. 2015 Aug 18;314(7):677-86. [http://jama.jamanetwork.com/article.aspx?articleid=2428955 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26284719 PubMed]

=Additional information=
<references />
*[http://journal.publications.chestnet.org/data/Journals/CHEST/934919/11026.pdf ACCP Chest guidelines for antithrombotic therapy for venous thromboembolic disease (2016)]
*[http://journal.publications.chestnet.org/issue.aspx?journalid=99&issueid=23443&direction=P ACCP Chest Guidelines (2012)] - Antithrombotic Therapy and Prevention of Thrombosis, 9th edition (2012)
**[http://journal.publications.chestnet.org/article.aspx?articleID=1159399 Executive summary] [http://journal.publications.chestnet.org/data/Journals/CHEST/23443/chest_141_2_suppl_7S.pdf PDF]
*Bleeding risk on anticoagulation: [http://www.globalrph.com/has-bled-score.htm HAS-BLED]; [http://www.globalrph.com/hemorr2hages-bleeding-risk.htm HEMORR2HAGES]

[[Category:Venous thromboembolism (VTE) regimens]]
[[Category:Disease-specific pages]]
[[Category:Thrombotic disorders]]
